Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

作者： Rafael Rosell , Enric Carcereny , Radj Gervais , Alain Vergnenegre , Bartomeu Massuti

DOI: 10.1016/S1470-2045(11)70393-X

关键词:

摘要: BACKGROUND: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell …

sciencedirect.com 本地加速

elsevier.com 本地加速

参考文章(23)

Koichi Goto, Yukito Ichinose, Yuichiro Ohe, Nobuyuki Yamamoto, Shunichi Negoro, Kazuto Nishio, Yohji Itoh, Haiyi Jiang, Emma Duffield, Rose McCormack, Nagahiro Saijo, Tony Mok, Masahiro Fukuoka, Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 7, pp. 115- 121 ,(2012) , 10.1097/JTO.0B013E3182307F98

L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Science Translational Medicine. ,vol. 3, ,(2011) , 10.1126/SCITRANSLMED.3002003

David S Ettinger, Wallace Akerley, Gerold Bepler, Matthew G Blum, Andrew Chang, Richard T Cheney, Lucian R Chirieac, Thomas A D'Amico, Todd L Demmy, Apar Kishor P Ganti, Ramaswamy Govindan, Frederic W Grannis, Thierry Jahan, Mohammad Jahanzeb, David H Johnson, Anne Kessinger, Ritsuko Komaki, Feng-Ming Kong, Mark G Kris, Lee M Krug, Quynh-Thu Le, Inga T Lennes, Renato Martins, Janis O'Malley, Raymond U Osarogiagbon, Gregory A Otterson, Jyoti D Patel, Katherine M Pisters, Karen Reckamp, Gregory J Riely, Eric Rohren, George R Simon, Scott J Swanson, Douglas E Wood, Stephen C Yang, None, Non-small-cell lung cancer The Lancet. ,vol. 378, pp. 1727- 1740 ,(2011) , 10.1016/S0140-6736(10)62101-0

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938

Daniel B. Costa, Susumu Kobayashi, Daniel G. Tenen, Mark S. Huberman, Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer. ,vol. 58, pp. 95- 103 ,(2007) , 10.1016/J.LUNGCAN.2007.05.017

Hongbin Ji, Danan Li, Liang Chen, Takeshi Shimamura, Susumu Kobayashi, Kate McNamara, Umar Mahmood, Albert Mitchell, Yangping Sun, Ruqayyah Al-Hashem, Lucian R. Chirieac, Robert Padera, Roderick T. Bronson, William Kim, Pasi A. Jänne, Geoffrey I. Shapiro, Daniel Tenen, Bruce E. Johnson, Ralph Weissleder, Norman E. Sharpless, Kwok-Kin Wong, The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies Cancer Cell. ,vol. 9, pp. 485- 495 ,(2006) , 10.1016/J.CCR.2006.04.022

William Pao, Juliann Chmielecki, Rational, biologically based treatment of EGFR -mutant non-small-cell lung cancer Nature Reviews Cancer. ,vol. 10, pp. 760- 774 ,(2010) , 10.1038/NRC2947

Rafael Rosell, Teresa Moran, Cristina Queralt, Rut Porta, Felipe Cardenal, Carlos Camps, Margarita Majem, Guillermo Lopez-Vivanco, Dolores Isla, Mariano Provencio, Amelia Insa, Bartomeu Massuti, Jose Luis Gonzalez-Larriba, Luis Paz-Ares, Isabel Bover, Rosario Garcia-Campelo, Miguel Angel Moreno, Silvia Catot, Christian Rolfo, Noemi Reguart, Ramon Palmero, José Miguel Sánchez, Roman Bastus, Clara Mayo, Jordi Bertran-Alamillo, Miguel Angel Molina, Jose Javier Sanchez, Miquel Taron, None, Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer The New England Journal of Medicine. ,vol. 361, pp. 958- 967 ,(2009) , 10.1056/NEJMOA0904554

Lecia V. Sequist, Renato G. Martins, David Spigel, Steven M. Grunberg, Alexander Spira, Pasi A. Jänne, Victoria A. Joshi, David McCollum, Tracey L. Evans, Alona Muzikansky, Georgiana L. Kuhlmann, Moon Han, Jonathan S. Goldberg, Jeffrey Settleman, A. John Iafrate, Jeffrey A. Engelman, Daniel A. Haber, Bruce E. Johnson, Thomas J. Lynch, First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations Journal of Clinical Oncology. ,vol. 26, pp. 2442- 2449 ,(2008) , 10.1200/JCO.2007.14.8494

10.

Katerina Politi, Maureen F Zakowski, Pang-Dian Fan, Emily A Schonfeld, William Pao, Harold E Varmus, Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors Genes & Development. ,vol. 20, pp. 1496- 1510 ,(2006) , 10.1101/GAD.1417406

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

来源期刊

我的账户

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

来源期刊

相似文章 10

我的账户